
    
      After successful screening, eligible patients will be randomly allocated to one of the two
      study arms, either receiving MYL-1401H or Neulasta.

      Randomization is 2:1 to MYL-1401H or Neulasta, respectively.

      Subjects will receive first of six cycles of background therapy (Docetaxel, Doxorubicin,
      Cyclophosphamide [TAC]) on day 1. Treatment with study drug (either MYL-1401H or Neulasta) is
      scheduled on Day 2 of each cycle, at least 24 hours after chemotherapy administration.

      Duration of each cycle is 3 weeks.

      Follow-up visit is scheduled 24 weeks after the first administration of study drug.
    
  